Arcadia Biosciences, Inc. (RKDA)
NASDAQ: RKDA · Real-Time Price · USD
3.710
+0.050 (1.37%)
Nov 24, 2025, 4:00 PM EST - Market closed
Arcadia Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 5.17 | 5.05 | 4.45 | 5 | 6.78 | 8.03 | Upgrade | |
Revenue Growth (YoY) | 12.31% | 13.27% | -10.87% | -26.30% | -15.61% | 587.25% | Upgrade |
Cost of Revenue | 3.08 | 2.86 | 2.07 | 2.99 | 9 | 8.85 | Upgrade |
Gross Profit | 2.09 | 2.18 | 2.39 | 2 | -2.22 | -0.81 | Upgrade |
Selling, General & Admin | 8.09 | 9.64 | 8.23 | 9.22 | 22.09 | 16.4 | Upgrade |
Research & Development | 0 | 0 | 0 | - | - | - | Upgrade |
Operating Expenses | 8.09 | 9.64 | 8.24 | 9.22 | 22.09 | 16.4 | Upgrade |
Operating Income | -6 | -7.46 | -5.85 | -7.22 | -24.31 | -17.21 | Upgrade |
Interest Expense | - | - | - | - | -0.02 | -0.05 | Upgrade |
Interest & Investment Income | 0.58 | 0.78 | 0.7 | 0.29 | - | - | Upgrade |
Other Non Operating Income (Expenses) | -2.2 | -1.44 | 0.09 | 2.9 | 8.07 | 6.61 | Upgrade |
EBT Excluding Unusual Items | -7.63 | -8.12 | -5.07 | -4.02 | -16.26 | -10.65 | Upgrade |
Merger & Restructuring Charges | - | - | - | - | -0.85 | -0.07 | Upgrade |
Impairment of Goodwill | - | - | - | - | -1.65 | - | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | 1.14 | 10.22 | 9.51 | Upgrade |
Gain (Loss) on Sale of Assets | 0.75 | 4 | 0.03 | 0.31 | -0.5 | - | Upgrade |
Asset Writedown | -0.15 | -0.19 | -0.28 | -1.29 | -8.43 | -4.31 | Upgrade |
Other Unusual Items | 2 | - | - | 0.07 | 1.33 | -0.64 | Upgrade |
Pretax Income | -5.03 | -4.31 | -5.32 | -3.79 | -16.13 | -6.15 | Upgrade |
Income Tax Expense | 0.01 | 0.01 | 0.01 | 0.01 | 0 | -0.12 | Upgrade |
Earnings From Continuing Operations | -5.04 | -4.32 | -5.33 | -3.81 | -16.13 | -6.03 | Upgrade |
Earnings From Discontinued Operations | -0.03 | -2.72 | -8.66 | -11.8 | - | - | Upgrade |
Net Income to Company | -5.07 | -7.04 | -13.99 | -15.61 | -16.13 | -6.03 | Upgrade |
Minority Interest in Earnings | - | - | 0.01 | 0.24 | 1.47 | 1.37 | Upgrade |
Net Income | -5.07 | -7.04 | -13.98 | -15.38 | -14.66 | -4.66 | Upgrade |
Net Income to Common | -5.07 | -7.04 | -13.98 | -15.38 | -14.66 | -4.66 | Upgrade |
Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 1 | 0 | Upgrade |
Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 1 | 0 | Upgrade |
Shares Change (YoY) | 0.28% | 10.22% | 106.37% | 12.66% | 113.68% | 56.51% | Upgrade |
EPS (Basic) | -3.71 | -5.16 | -11.30 | -25.65 | -27.56 | -18.70 | Upgrade |
EPS (Diluted) | -3.71 | -5.16 | -11.30 | -25.65 | -27.56 | -18.70 | Upgrade |
Free Cash Flow | -6.09 | -9.64 | -15.3 | -14.05 | -26.88 | -32.55 | Upgrade |
Free Cash Flow Per Share | -4.46 | -7.07 | -12.37 | -23.44 | -50.52 | -130.75 | Upgrade |
Gross Margin | 40.40% | 43.29% | 53.62% | 40.10% | -32.80% | -10.13% | Upgrade |
Operating Margin | -115.99% | -147.83% | -131.32% | -144.43% | -358.58% | -214.26% | Upgrade |
Profit Margin | -97.95% | -139.50% | -313.90% | -307.70% | -216.22% | -57.94% | Upgrade |
Free Cash Flow Margin | -117.67% | -191.14% | -343.49% | -281.15% | -396.39% | -405.19% | Upgrade |
EBITDA | -5.95 | -7.35 | -5.56 | -6.74 | -23.27 | -16.55 | Upgrade |
EBITDA Margin | -115.00% | -145.59% | -124.88% | -134.84% | - | -206.02% | Upgrade |
D&A For EBITDA | 0.05 | 0.11 | 0.29 | 0.48 | 1.05 | 0.66 | Upgrade |
EBIT | -6 | -7.46 | -5.85 | -7.22 | -24.31 | -17.21 | Upgrade |
EBIT Margin | -115.99% | -147.83% | -131.32% | -144.43% | - | -214.26% | Upgrade |
Revenue as Reported | 5.17 | 5.05 | 4.45 | 5 | 6.78 | 8.03 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.